VC: MAP leads with $25M round



MAP Pharmaceuticals leads with $25.2 million round.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

MAP Pharmaceuticals
Mountain View, CA

$25.25 million
third round

Brookside Capital

The money will be used primarily to advance the Phase II clinical development of the company's two lead drug candidates for the treatment of asthma and migraine.

CoLucid Pharmaceuticals
Indianapolis

$16 million
first

Domain Associates, Pappas Ventures

The company was formed with a novel clinical stage migraine molecule licensed from Eli Lilly.

Chlorogen
Creve Coeur, MO

$6 million
second

Burrill & Co.

Chlorogen produces therapeutic proteins in tobacco.

Neuroptix
Acton, MA

$500,000
Angel

Launchpad Venture Group

Neuroptix is focused on the diagnosis and management of Alzheimer's and other degenerative neurological and ophthalmologic disorders.

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.